Dr. Giovanna Muggiolu joined LXRepair in Novem­ber 2017 as Head of Re­search and De­vel­op­ment. Her re­search fo­cus­es on de­fining a DNA Repair enzyma­tic sig­na­ture that char­ac­ter­izes the pa­tient’s re­sponse to ra­dio and chemo­ther­a­py. Her pri­or re­search fo­cused on molec­u­lar mech­a­nisms in­duced by ion­iz­ing ra­di­a­tion for emerg­ing can­cer ther­a­pies. She re­ceived her M.A. from the Uni­ver­si­ty of Tu­rin in Med­i­cal Biotech­nolo­gies and PhD from Bor­deaux Uni­ver­si­ty in Cel­lu­lar Bi­ol­o­gy and Physio­patho­lo­gy.

Bertrand Treillard joined LX­Re­pair in Septem­ber 2017 as an En­gi­neer in Re­search and De­vel­op­ment and is par­tic­u­lar­ly in­volved in the de­vel­op­ment of LXRe­pair di­ag­nos­tic tests. He spe­cial­izes in biotech­nol­o­gy and molec­u­lar di­ag­nos­tics. Pri­or to join­ing LX­Re­pair, Bertrand worked on the tech­ni­cal de­vel­op­ment of an in vit­ro di­ag­nos­tic test at Im­munID, al­low­ing to ob­tain CE mark­ing for the test and CLIA cer­ti­fi­ca­tion for the Lab. ­

Xavier Tatin joined LX­Re­pair in 2018 and he is cur­rent­ly do­ing a PhD in col­lab­o­ra­tion with a CEA lab. Grad­u­at­ed in 2017 from Agro­Paris­Tech he also holds a master’s de­gree in biotech­nol­o­gy. His doc­tor­al work is focus­ed on the de­vel­op­ment and the val­i­da­tion of a new en­zy­mat­ic as­say for the char­ac­ter­i­za­tion of DNA dou­ble-strand breaks re­pair.

He also worked at the Uni­ver­si­ty of Otago in New Zealand and at Nova South­eastern Uni­ver­si­ty (FL, USA).

Robin Dumas joined LX­Repair in 2017 and cur­rent­ly holds the po­si­tion of mar­ket­ing as­sis­tant. He has a back­ground in biotech­nol­o­gy (Mas­ter de­gree) from the Uni­ver­si­ty of Sci­ence of Mont­pel­lier and he is de­vel­op­ing new skills by do­ing a spe­cial­iza­tion in Man­age­ment of Tech­nol­o­gy and In­no­va­tion at Gre­no­ble Ecole de Man­age­ment.

Robin was a tem­po­ra­ry mem­ber of the All­Seq (US) team that work­ed on es­tab­lish­ing the world’s first on­line se­quenc­ing mar­ket­place.

Sophie Manuel is an ex­pe­ri­enced Car­di­ol­o­gist. She also works as an au­ricu­lo-ther­a­pist in can­cerol­o­gy or as an clin­i­cal and mar­ket­ing ex­pert.

FX Desforges is an experienced Man­ager of High Techno­lo­gies/In­no­va­tive start-ups com­pa­nies in var­i­ous mar­kets (Health, Mar­itime, In­stru­men­ta­tion, ….) with a broad ex­pe­ri­ence in var­i­ous do­mains (Sales & Mar­ket­ing of In­no­va­tive Pro­ducts, Fi­nance, Busi­ness Plan, HR, R&D, …). Re­cent­ly, he was CEO of Presto­diag SAS, a di­ag­nos­tic com­pa­ny in food safe­ty and pre­vi­ous­ly CEO of Ge­newave SAS which merged with Mo­bidiag in 2014.

François Xavier grad­u­at­ed from Ecole Nor­male Su­perieure in 1983 and earned a PhD from Uni­ver­si­ty of Limoges in 1989.